SCHEMBL438243

SCHEMBL438243

CN(CCl)C(=O)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
HDAC1 Q13547 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
ALDH1A1 P00352 2/20 0.48
TRPA1 O75762 1/20 0.48
MAPK1 P28482 1/20 0.48
GSK3B P49841 1/20 0.48
HIF1A Q16665 1/20 0.48
HPGD P15428 1/20 0.47
HSD11B1 P28845 1/20 0.47
EGFR P00533 1/20 0.46
ERBB2 P04626 1/20 0.46
ACHE P22303 1/20 0.46
RECQL P46063 1/20 0.46
CDK4 P11802 1/20 0.45
CCND1 P24385 1/20 0.45
MLYCD O95822 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11210779 0.83 KMT2A (0.56) KMT2AMEN1HDAC1HDAC6ALDH1A1
SCHEMBL3362719 0.81 KMT2A (0.55) KMT2AMEN1HDAC1HDAC6ALDH1A1
SCHEMBL1003249 0.81 ALDH1A1 (0.58) KMT2AMEN1HDAC1HDAC6ALDH1A1
SCHEMBL3902478 0.80 HSD11B1 (0.52) KMT2AMEN1ALDH1A1TRPA1MAPK1
SCHEMBL9377725 0.80 EGFR (0.51) KMT2AMEN1HDAC6EGFRERBB2
SCHEMBL20033534 0.79 KMT2A (0.53) KMT2AMEN1HDAC1HDAC6ALDH1A1
SCHEMBL17629660 0.79 KMT2A (0.53) KMT2AMEN1HDAC1HDAC6ALDH1A1
SCHEMBL4585832 0.79 KMT2A (0.53) KMT2AMEN1HDAC1HDAC6ALDH1A1
SCHEMBL2282162 0.79 KMT2A (0.53) KMT2AMEN1HDAC1HDAC6ALDH1A1
SCHEMBL294286 0.79 KMT2A (0.53) KMT2AMEN1HDAC1HDAC6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023122780-A9 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
EP-3049391-A1 INDOL AND INDAZOL DERIVATIVES F. Hoffmann-La Roche AG (CH) 2016-08-03 EP disclosed
WO-2015044072-A1 INDOL AND INDAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2015-04-02 WO disclosed
EP-2432764-A1 SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS ClanoTech AB (SE) 2012-03-28 EP disclosed
US-20120065199-A1 SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS CLANOTECH AB (SE) 2012-03-15 US disclosed
WO-2010133669-A1 SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS CLANOTECH AB (SE) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065199-A1 SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS FLT1, FLT4, VEGFA KMT2A 4799/4885MEN1 2837/4885HDAC1 4239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.